Abstract
Background The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five months ago. However, the safety of the third (booster) dose has not been fully established yet.
Objective Evaluate the short-term, self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.
Design A prospective observational study, in which participants are equipped with a smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, starting seven days before the vaccination.
Setting An Israel-wide third (booster) vaccination campaign.
Participants A group of 1503 (18+ years of age) recipients of at least one dose of the BNT162b2 vaccine between December 20, 2020, and September 6, 2021, out of a larger cohort of 2,848 prospective study participants. 1,231 of the participants were recipients of the third vaccine dose.
Measurements Daily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate and heart rate variability were continuously measured by Garmin Vivosmart 4 smartwatches.
Results Local and systemic reactions reported following the third (booster) dose administration are similar to those reported following the second dose and considerably greater than those reported following the first dose. Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further support this finding. These measures returned to their baseline levels within three days from inoculation with the third dose. These trends were consistent regardless of age, gender or the existence of an underlying medical condition.
Limitations Participants may not adequately represent the vaccinated population in Israel and elsewhere.
Conclusion Our work further supports the safety of a third COVID-19 BNT162b2 mRNA (booster) vaccine dose from both a subjective and an objective perspective.
Primary funding source European Research Council (ERC) project #949850.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is a prospective observational study and does not include any medical intervention.
Funding Statement
This research was supported by the European Research Council (ERC) project #949850 and the Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine Partnership program. MLB and GG received support from the Koret foundation grant for Smart Cities and Digital Living 2030.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Before participating in the study, all subjects were advised, both orally and in writing, as to the nature of the study and gave written informed consent. The study was approved by MHS' Helsinki institutional review board, protocol number 0122-20-MHS.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Researchers interested in obtaining an aggregated version of the data sufficient to reproduce the results reported in this paper should contact the corresponding author.
